OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug developers given the persistent unmet need for more effective and safe therapies, particularly those with a novel and distinct mechanism of action that strongly correlates with the nature of this type of pain. OA pain is predominantly treated with cost-effective generic NSAIDs and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics, new combinations of existing NSAIDs that attempt to mitigate side effects, and intra-articular injections are also frequently prescribed in later lines of therapy. Emerging therapies, such as biological drugs from Pfizer / Eli Lilly and Regeneron / Teva / Mitsubishi Tanabe Pharma targeting NGF, and the increasing number of patients diagnosed with OA pain due to lifestyle influences will be key drivers for growth through 2028.
- How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse / misuse with opioid analgesics?
- What effect will the recent launches of new analgesics such as Flexion Therapeutics' Zilretta and Iroko’s Vivlodex continue to have on the treatment paradigm?
- What will the impact of a new drug class, the anti-NGF biologics, be on the treatment landscape given their demonstrably robust efficacy tempered by lingering concerns about safety issues seen in clinical trials?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Thirteen country-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence and drug-treated rates of OA pain by country.
Emerging therapies: Phase III / preregistration / registration: 8 drugs; Phase II: 7 drugs; coverage of select Phase I products.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key analgesics through 2028, segmented by brands / generics.
Key companies: Acorda Therapeutics, Ampio Pharmaceuticals, Astellas, Centrexion, Collegium Pharmaceutical, Eli Lilly, Flexion Therapeutics, Iroko Pharmaceuticals, Mitsubishi Tanabe Pharma, Nektar Therapeutics, Pfizer, Purdue Pharma, Regeneron, Samumed, Teva.
Key drugs: acetaminophen / hydrocodone, Ampion, cebranopadol, celecoxib, CNTX-4975, fasinumab, Hysingla ER (hydrocodone ER), lorecivivint, Nucynta IR / ER (tapentadol IR / ER), oxycodegol (NKTR-181), oxycodone CR (OxyContin, generics), oxycodone ER (Xtampza ER), Qutenza (8% capsaicin patch), tanezumab, tramadol, Vivlodex (meloxicam, low dose), Zilretta (triamcinolone ER, injectable).
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Joyce Spadafora, A.L.M.
Joyce Spadafora, A.L.M., is a senior analyst on the CNS/Ophthalmology Disorders team. She authors content on various chronic pain, psychiatric, and neurological indications. Prior to joining the company, she spent several years in the biotech industry focusing on new product development and consulting. She holds a master’s degree in extension studies in psychology from Harvard University and a bachelor’s of science in mechanical engineering with biology from the Massachusetts Institute of Technology.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.
Bethany A. Kiernan, Ph.D.
Bethany A. Kiernan, Ph.D., is a senior director on the CNS/Ophthalmology Disorders team at Clarivate. She manages and supports a team of business insights analysts in producing both syndicated and custom market research analyses in a range of psychiatry and pain indications. Dr. Kiernan has extensive experience in market forecasting and broad knowledge across a range of CNS disorders, including depression, bipolar disorder, and chronic pain indications. Her previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. She earned her doctorate in neurosciences from Case Western Reserve University.
Audreza Das, P.G. Dip.
Audreza Das, P.G. Dip., B.E., is a senior analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. She has authored content on neuropathic pain, age-related macular degeneration, attention-deficit/hyperactivity disorder, unipolar depression, bipolar disorder, treatment-related depression, postherpetic neuralgia, painful diabetic neuropathy, and migraine. Ms. Das obtained her P.G. Dip. in cancer immunology and biotechnology from the University of Nottingham and a B.E. in biotechnology from the Birla Institute of Technology.
Shefali Gulati, M.B.A.
Shefali Gulati, M.B.A., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She has authored several CNS/Ophthalmology reports, including U.S. Treatment Algorithms, Unmet need, Special topics. Previously, Ms. Gulati was a knowledge management associate with ZS Associates, where she worked on multiple client projects pertaining to real-world claims data analysis, opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds an M.B.A. in pharmaceutical management from the National Institute of Pharmaceutical Education and Research and a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research.